Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05950711 · ClinicalTrials.gov registry record · Phase 4
Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
A Phase 4 study of Major Depressive Disorder, sponsored by Ohio State University.
- Active
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT05950711 is a Phase 4 study of Major Depressive Disorder that is active but no longer recruiting, run by Ohio State University. The registered enrollment target is 21 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05950711, a Phase 4 study of Major Depressive Disorder, is active but no longer recruiting, sponsored by Ohio State University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the feasibility of combining IV ketamine, a rapid acting antidepressant, with a course of Mindfulness-Based Cognitive Therapy (MBCT), for the initial and maintenance treatment of depression.
Conditions Studied
Interventions
- OTHER Combination use of MBCT and IV Ketamine
Study Locations (1)
Ohio
- Harding Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05950711
The ClinicalTrials.gov registry entry for NCT05950711 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (94% lower). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Combination use of MBCT and IV Ketamine is the first listed.
NCT05950711 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05950711 about?
NCT05950711 is a clinical study titled "Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study". The purpose of this study is to assess the feasibility of combining IV ketamine, a rapid acting antidepressant, with a course of Mindfulness-Based Cognitive Therapy (MBCT), for the initial and maintenance treatment of depression.
What is the current status of trial NCT05950711?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2022-03-30. Estimated completion is 2026-11-30.
What conditions does trial NCT05950711 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05950711?
The interventions under investigation include: Combination use of MBCT and IV Ketamine (OTHER).
Who is sponsoring clinical trial NCT05950711?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05950711 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.